Guy Carpenter Forms New Global Strategic Advisory Organization to Provide Clients with Enhanced Solutions
Guy Carpenter & Company, LLC, a leading global risk and reinsurance specialist and a wholly owned subsidiary of Marsh & McLennan Companies (NYSE:MMC), today announced a newly-created Global Strategic Advisory organization comprised of its Advisory, Analytics, Structured Risk, M&A Advisory, Lloyd’s Capital, and Business Intelligence capabilities.
Rob Bentley has been appointed President of Global Strategic Advisory. Mr. Bentley re-joins Guy Carpenter from Marsh, where most recently he ran the US and Canada Division. Mr. Bentley will report to Peter Hearn, President & CEO of Guy Carpenter, and will be based in New York. Mr. Bentley is a 30-year veteran of insurance and reinsurance broking, with significant executive and operational experience in analytics and software development.
“Guy Carpenter’s Strategic Advisory organization will add value to clients by delivering a globally consistent methodology for our advisory tools and capabilities,” said Mr. Hearn. “I am pleased to welcome Rob back to Guy Carpenter in this important leadership role.”
In connection with the creation of the Global Strategic Advisory organization, Vicky Carter has been appointed Vice Chairman of Global Strategic Advisory. Ms. Carter will also report to Mr. Hearn, and will continue to be based in London. A reinsurance industry veteran with more than 35 years of experience, most recently Ms. Carter served as Vice Chair of Guy Carpenter’s international operations, and previously has held multiple prominent leadership roles in the industry.
“The new Guy Carpenter Global Strategic Advisory organization reflects our commitment to delivering a high-quality and consistently compelling global client experience,” said Mr. Hearn. “Vicky is a seasoned executive who will work closely with our major clients and prospects around the world to help them grow profitably by identifying strategic opportunities.”
About Guy Carpenter
Guy Carpenter & Company, LLC is a leading global risk and reinsurance specialist. Since 1922, the company has delivered integrated reinsurance and capital market solutions to clients across the globe. As a most trusted and valuable reinsurance broker and strategic advisor, Guy Carpenter leverages its intellectual capital to anticipate and solve for a range of business challenges and opportunities on behalf of its clients. With over 2,300 professionals in more than 60 offices around the world, Guy Carpenter delivers a powerful combination of broking expertise, strategic advisory services and industry-leading analytics to help clients achieve profitable growth. For more information on Guy Carpenter’s complete line-of-business expertise and range of business units, including GC Specialties, GC Analytics® , GC Fac® , Global Strategic Advisory, GC Securities*, Client Services and GC Micro Risk Solutions® , please visit www.guycarp.com and follow Guy Carpenter on LinkedIn and Twitter @GuyCarpenter .
Guy Carpenter is a wholly owned subsidiary of Marsh & McLennan Companies (NYSE: MMC), a global professional services firm offering clients advice and solutions in the areas of risk, strategy, and people. With annual revenue of $13 billion and 60,000 colleagues worldwide, Marsh & McLennan Companies provides analysis, advice, and transactional capabilities to clients in more than 130 countries through: Marsh , a leader in insurance broking and risk management; Mercer , a leader in talent, health, retirement, and investment consulting; and Oliver Wyman , a leader in management consulting. Marsh & McLennan is committed to being a responsible corporate citizen and making a positive impact in the communities in which it operates. Visit www.mmc.com for more information and follow us on LinkedIn and Twitter @MMC_Global .
*Securities or investments, as applicable, are offered in the United States through GC Securities, a division of MMC Securities LLC, a US registered broker-dealer and member FINRA /NFA/SIPC . Main Office: 1166 Avenue of the Americas, New York, NY 10036. Phone: (212) 345-5000. Securities or investments, as applicable, are offered in the European Union by GC Securities, a division of MMC Securities (Europe) Ltd. (MMCSEL), which is authorized and regulated by the Financial Conduct Authority, main office 25 The North Colonnade, Canary Wharf, London E14 5HS. Reinsurance products are placed through qualified affiliates of Guy Carpenter & Company, LLC. MMC Securities LLC, MMC Securities (Europe) Ltd. and Guy Carpenter & Company, LLC are affiliates owned by Marsh & McLennan Companies. This communication is not intended as an offer to sell or a solicitation of any offer to buy any security, financial instrument, reinsurance or insurance product. **GC Analytics is a registered mark with the U.S. Patent and Trademark Office.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
FL-GA-TELESIS11.12.2017 06:03 | pressemeddelelse
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske
ASTRAZENECA10.12.2017 23:47 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials
NJ-CELGENE/BLUEBIRD-BIO10.12.2017 16:32 | pressemeddelelse
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting
GA-GILEAD-SCIENCES/KITE10.12.2017 16:32 | pressemeddelelse
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
MA-TAKEDA/SEATTLE10.12.2017 14:02 | pressemeddelelse
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
ASTRAZENECA9.12.2017 19:02 | pressemeddelelse
AstraZeneca’s Calquence (acalabrutinib) Demonstrates Activity in Relapsed or Refractory Mantle Cell Lymphoma Trial
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum